{
    "clinical_study": {
        "@rank": "144575", 
        "arm_group": {
            "arm_group_label": "Misoprostol at clinic", 
            "arm_group_type": "Experimental", 
            "description": "Eligible women will receive 200 mg mifepristone to be administered at home or at the clinic and will receive either 800 \u00b5g misoprostol buccally (study 1) or 800 \u00b5g misoprostol sublingually (study 2) to self administer at home.\nParticipants will be asked to return to the hospital 14 days later for a follow-up visit."
        }, 
        "brief_summary": {
            "textblock": "These pilot studies are designed as open label studies to investigate the acceptability of\n      200 mg mifepristone followed 24-48 hours later by either  1) 800 \u00b5g misoprostol administered\n       buccally or 2) 800 \u00b5g misoprostol administered sublingually  for medical abortion in\n      gestations 78-84 days' LMP. They will be done consecutively.\n\n      Findings from the pilot studies will guide the development of a larger, multi-site study to\n      investigate the efficacy of outpatient medical abortion regimens for women with gestations\n      from 78 - 84 days LMP.  In that end, the pilots seek to collect information on the\n      acceptability of an outpatient medical abortion regimen of 200 mg oral mifepristone followed\n      by either 800 mcg misoprostol delivered either buccally or sublingually safe acceptable?\n      Women's rating of the tolerability of any side effects will also be documented."
        }, 
        "brief_title": "Acceptability of an Out-patient Regimen of Medical Abortion With Mifepristone and 800 Mcg Misoprostol Administered at 78-84 Days Gestation", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "condition": "Medical Abortion", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Seeking abortion services\n\n          -  Have an intrauterine pregnancy 78 days through 84 days' LMP\n\n          -  Be willing and able to sign consent forms\n\n          -  Agree to comply with study procedures and visit schedule\n\n          -  Be living with 30 minutes from the hospital\n\n        Exclusion Criteria:\n\n          -  Does not meet the inclusion criteria outlined above"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01856985", 
            "org_study_id": "1010"
        }, 
        "intervention": [
            {
                "arm_group_label": "Misoprostol at clinic", 
                "intervention_name": "Misoprostol", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Misoprostol at clinic", 
                "intervention_name": "Mifepristone", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Mifepristone", 
                "Misoprostol"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Medical abortion", 
            "Misoprostol", 
            "Mifepristone"
        ], 
        "lastchanged_date": "October 9, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Ho Chi Minh City", 
                    "country": "Vietnam"
                }, 
                "name": "Hung Vuong Hospital"
            }
        }, 
        "location_countries": {
            "country": "Vietnam"
        }, 
        "number_of_arms": "1", 
        "official_title": "The Acceptability of an Out-patient Regimen of Medical Abortion With Mifepristone and 800 Mcg Misoprostol Administered Buccally or Sublingually at 78-84 Days Gestation: Two Pilot Studies", 
        "overall_official": [
            {
                "affiliation": "Gynuity Health Projects", 
                "last_name": "Beverly Winikoff, MD, MPH", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Gynuity Health Projects", 
                "last_name": "Jennifer Blum, MPH", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Center for Research and Consultancy in Reproductive Health", 
                "last_name": "Nguyen Thu Nhu Ngoc, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Gynuity Health Projects", 
                "last_name": "Dina F Abbas", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Vietnam: Hung Vuong Hospital", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Percentage of women who have undergone a successful abortion", 
            "safety_issue": "No", 
            "time_frame": "2 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01856985"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Women's acceptability of the assigned method.", 
                "safety_issue": "No", 
                "time_frame": "2 weeks"
            }, 
            {
                "description": "Side effects include nausea, vomiting, pain, diarrhea, fever. Asked women to rank as none, mild, moderate, severe. Used an acceptability scale (Very Acceptable v. Acceptable v. Neutral v. Unacceptable v. Very unacceptable v. Don't know) to ascertain acceptability among women", 
                "measure": "Side effects", 
                "safety_issue": "No", 
                "time_frame": "48 hours"
            }
        ], 
        "source": "Gynuity Health Projects", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gynuity Health Projects", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}